Expression of E-cadherin and syndecan-1 in axillary lymph node metastases of breast cancer with and without extracapsular extension

Journal of the Medical Association of Thailand

Volumn 91, Issue 7, 2008, Pages 1087-1092

  Thanakit, Voranuch ^a   Ruangvejvorachai, Preecha ^a   Sampatanukul, Pichet ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Breast cancer; E cadherin; Extracapsular extension; Syndecan 1

Indexed keywords

SYNDECAN; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CADHERINS; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL;

EID: 48249140702     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 2005; 11: 4083-9.
2. Leonard C, Corkill M, Tompkin J, Zhen B, Waitz D, Norton L, et al. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. J Clin Oncol 1995; 13: 47-53.
3. Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993; 72: 778-82.
4. Pierce LJ, Oberman HA, Strawderman MH, Lichter AS. Microscopic extracapsular extension in the axilla: is this an indication for axillary radiotherapy? Int J Radiat Oncol Biol Phys 1995; 33: 253-9.
5. Neri A, Marrelli D, Roviello F, De Stefano A, Guarnieri A, Pallucca E, et al. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer. Ann Surg Oncol 2005; 12: 246-53.
6. Evron E, Barzily L, Rakowsky E, Ben Baruch N, Sulkes J, Rizel S, et al. Postoperative loco-regional radiation therapy for breast cancer patients with four or more involved lymph nodes or extracapsular extension. Isr Med Assoc J 2005; 7: 439-42.
7. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001; 108: 165-7.
8. Zimmermann P, David G. The syndecans, tuners of transmembrane signaling. FASEB J 1999;13(Suppl): S91-100.
9. Rakha EA, Abd ER, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46: 685-93.
10. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo MF, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-83.
11. Hetelekidis S, Schnitt SJ, Silver B, Manola J, Bornstein BA, Nixon AJ, et al. The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys 2000; 46: 31-4.
12. Lundin M, Nordling S, Lundin J, Isola J, Wiksten JP, Haglund C. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 2005; 68: 306-13.
13. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67: 11-8.
14. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: R217-R222.
15. Bukholm IK, Nesland JM, Borresen-Dale AL. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. J Pathol 2000; 190: 15-9.
16. Leppa S, Vleminckx K, Van Roy F, Jalkanen M. Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent. J Cell Sci 1996; 109(Pt 6): 1393-403.